Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 11/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 10/20 | 0.42 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.34 |
| ▸ | BAD | Q92934 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | MMP3 | P08254 | 1/20 | 0.33 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
| ▸ | MMP13 | P45452 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22882228 | 0.87 | ESR1 (0.42) | ESR1ESR2BCL2L1BADCYP19A1 | |
| SCHEMBL1688041 | 0.82 | ESR2 (0.45) | ESR1ESR2CYP19A1NPC1CYP3A4 | |
| SCHEMBL1688005 | 0.80 | ESR2 (0.46) | ESR1ESR2CYP19A1NPC1CYP3A4 | |
| SCHEMBL1688018 | 0.78 | ESR2 (0.56) | ESR1ESR2CYP19A1NPC1CYP3A4 | |
| SCHEMBL1687994 | 0.76 | ESR2 (0.57) | ESR1ESR2CYP19A1NPC1CYP3A4 | |
| SCHEMBL1688033 | 0.74 | ESR2 (0.62) | ESR1ESR2CYP19A1NPC1CYP3A4 | |
| SCHEMBL14070931 | 0.69 | STS (0.39) | CYP19A1 | |
| SCHEMBL14070956 | 0.67 | STS (0.38) | — | |
| SCHEMBL4794533 | 0.66 | NFKB1 (0.41) | L3MBTL1 | |
| SCHEMBL14070944 | 0.66 | OPRL1 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120088825-A1 | COMPOUNDS WITH ACTIVITY AT ESTROGEN RECEPTORS | ACADIA PHARMACEUTICALS INC. (US) | 2012-04-12 | — | — | US | disclosed |
| US-8101651-B2 | Compounds with activity at estrogen receptors | ACADIA PHARMACEUTICALS INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-20090131510-A1 | COMPOUNDS WITH ACTIVITY AT ESTROGEN RECEPTORS | ACADIA PHARMACEUTICALS INC. | 2009-05-21 | — | — | US | disclosed |
| WO-2009055734-A1 | CONDENSED COMPOUNDS WITH ACTIVITY AT ESTROGEN RECEPTORS | ACADIA PHARMACEUTICALS INC. (US) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088825-A1 | COMPOUNDS WITH ACTIVITY AT ESTROGEN RECEPTORS | ESRRB, ESR2, ESRRA | ESR1 6/4885ESR2 2/4885BCL2L1 3712/4885 |
| US-20090131510-A1 | COMPOUNDS WITH ACTIVITY AT ESTROGEN RECEPTORS | ESRRB, ESR2, ESRRA | ESR1 6/4885ESR2 2/4885BCL2L1 3712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.